2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
629
pembrolizumab
559
Magnetic Resonance Spectroscopy
539
Carboplatin
423
Cyclophosphamide
371
Cisplatin
371
Biopsy
357
Paclitaxel
304
Nivolumab
301
Gemcitabine
299
Radiotherapy
270
Bevacizumab
238
Dexamethasone
207
fludarabine
205
Docetaxel
189
durvalumab
178
atezolizumab
176
Oxaliplatin
172
Fluorouracil
167
venetoclax
164
Rituximab
164
Pemetrexed
162
Radiation
159
Doxorubicin
159
Capecitabine
158
Radiosurgery
147
Etoposide
137
Ipilimumab
134
Leucovorin
133
Lenalidomide
130
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
trastuzumab duocarmazine
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled